scholarly journals TSH Compensates Thyroid-Specific IGF-I Receptor Knockout and Causes Papillary Thyroid Hyperplasia

2011 ◽  
Vol 25 (11) ◽  
pp. 1867-1879 ◽  
Author(s):  
Kathrin Müller ◽  
Dagmar Führer ◽  
Jens Mittag ◽  
Nora Klöting ◽  
Matthias Blüher ◽  
...  

Abstract Although TSH stimulates all aspects of thyroid physiology IGF-I signaling through a tyrosine kinase-containing transmembrane receptor exhibits a permissive impact on TSH action. To better understand the importance of the IGF-I receptor in the thyroid in vivo, we inactivated the Igf1r with a Tg promoter-driven Cre-lox system in mice. We studied male and female mice with thyroidal wild-type, Igf1r+/−, and Igf1r−/− genotypes. Targeted Igf1r inactivation did transiently reduce thyroid hormone levels and significantly increased TSH levels in both heterozygous and homozygous mice without affecting thyroid weight. Histological analysis of thyroid tissue with Igf1r inactivation revealed hyperplasia and heterogeneous follicle structure. From 4 months of age, we detected papillary thyroid architecture in heterozygous and homozygous mice. We also noted increased body weight of male mice with a homozygous thyroidal null mutation in the Igf1r locus, compared with wild-type mice, respectively. A decrease of mRNA and protein for thyroid peroxidase and increased mRNA and protein for IGF-II receptor but no significant mRNA changes for the insulin receptor, the TSH receptor, and the sodium-iodide-symporter in both Igf1r+/− and Igf1r−/− mice were detected. Our results suggest that the strong increase of TSH benefits papillary thyroid hyperplasia and completely compensates the loss of IGF-I receptor signaling at the level of thyroid hormones without significant increase in thyroid weight. This could indicate that the IGF-I receptor signaling is less essential for thyroid hormone synthesis but maintains homeostasis and normal thyroid morphogenesis.

1999 ◽  
pp. 149-159 ◽  
Author(s):  
T Modric ◽  
K Rajkumar ◽  
LJ Murphy

OBJECTIVE: IGF-I, IGF-I receptor and IGF-binding proteins (IGFBPs) are expressed in thyroid tissue and are associated with the function and growth of the thyroid. This study investigated the in vivo and in vitro effects of increased IGFBP-1 levels on the function and growth of the thyroid gland. DESIGN: Transgenic mice which constitutively overexpress IGFBP-1 were used. These mice have a phenotype consistent with partial inhibition of IGF-I action. METHODS: Thyroid growth, morphology and hormonogenesis were determined in transgenic mice treated with goitrogens, sodium perchlorate and methimazole. In vitro cell proliferation in thyroid follicles was assessed in response to IGF-I and TSH. RESULTS: Thyroid weight was increased in transgenic mice, relative to their body mass, whereas serum tri-iodothyronine (T(3)), thyroxine and T(3)-binding capacity were reduced, compared with wild-type. While an inverse relationship between T(3) and TSH was observed in both groups of goitrogen-treated mice, the slope of the line of best fit was less steep in transgenic mice compared with wild-type mice. Thyroid growth was less marked in transgenic than wild-type mice in response to goitrogens, although TSH levels were higher in goitrogen-treated transgenics. In vitro proliferative response of isolated thyroid follicles to IGF-I, but not to TSH, was reduced in transgenic, compared with wild-type mice. CONCLUSIONS: The results of this study suggest that, while overexpression of IGFBP-1 attenuates IGF-I action in vitro, it enhances thyroid growth in vivo, presumably as a result of perturbations in thyroid function at multiple levels.


2008 ◽  
Vol 294 (2) ◽  
pp. E291-E299 ◽  
Author(s):  
Gaëlle Prost ◽  
Françoise Bernier-Valentin ◽  
Yvonne Munari-Silem ◽  
Samia Selmi-Ruby ◽  
Bernard Rousset

Thyroid epithelial cells communicate through gap junctions formed from connexin (Cx)32, Cx43, and Cx26. We previously reported that reexpression of Cx32 in “gap junction-deficient” FRTL-5 and FRT thyroid cell lines induces a reduction of cell proliferation rate and an activation of expression of cell differentiation. The present study aimed at determining whether Cx32 could exert similar regulatory functions in vivo. We investigated morphological and functional characteristics of thyroid gland of Cx32-deficient mice (Cx32-KO), mice overexpressing Cx32 selectively in the thyroid (Cx32-T+), and Cx32-KO mice with a thyroid-selective Cx32 complementation obtained by crossing Cx32-KO and Cx32-T+ mice. In basal conditions, Cx32-KO mice did not present any detectable thyroid alteration, whereas Cx32-T+ mice showed a thyroid hypoplasia (20% reduction) associated with a slight increase in thyroid functional activity. Under thyrotropin stimulation (following sodium perchlorate treatment), Cx32-KO mice developed a larger goiter (≤65% increase) than wild-type littermates, whereas Cx32-T+ mice exhibited the same thyroid hyperplasia as wild-type mice. Restoration of Cx32 expression in the thyroid of Cx32-KO mice abrogated the thyroid growth increase related to Cx32 deficiency. All together, these data show that Cx32 acts as a downregulator of growth of thyroid gland; an excess of Cx32 limits growth of thyroid cells in the basal state, whereas a lack of Cx32 confers an additional growth potential to TSH-stimulated thyroid cells.


1990 ◽  
Vol 123 (5) ◽  
pp. 511-518 ◽  
Author(s):  
Jaeduk Noh ◽  
Noboru Hamada ◽  
Hifumi Saito ◽  
Midori Yoshimoto ◽  
Hiroyuki Iwasaki ◽  
...  

Abstract. Recently, thyroid microsomal antigen was identified as thyroid peroxidase, and thyroid microsomal antibody was found to inhibit thyroid peroxidase activity in vitro. We investigated the possibility that anti-microsomal antibody inhibits the iodination of tyrosine, in vivo. Immunoglobulin G with or without anti-microsomal antibody from hypothyroid patients with goitrous Hashimoto's thyroiditis inhibited thyroid hormone synthesis in cultured slices of normal human thyroid tissue. IgGs with anti-microsomal antibody inhibited 125I thyroidal uptake and thyroid hormone synthesis stimulated by TSH more than normal IgG did. However, the same results were obtained with IgGs without anti-microsomal antibody. This effect did not involve anti-microsomal antibody, anti-thyroglobulin antibody, TSH-binding inhibitor immunoglobulin, thyroid stimulation-blocking immunoglobulin, or the cAMP level of the thyroid tissue. The ratio of organic I to inorganic I with stimulation by TSH in slices incubated with IgG from hypothyroid patients with goitrous Hashimoto's thyroiditis or normal IgG was not significantly different, but was significantly higher in slices incubated with methylmercaptoimidazole. Therefore, IgG from hypothyroid patients with goitrous Hashimoto's thyroiditis mainly suppressed 125I thyroidal uptake, rather than inhibiting thyroid peroxidase activity. In addition, this IgG was present in the serum of 11 of the 12 hypothyroid patients with Hashimoto's thyroiditis studied. This IgG may be involved in the mechanism that causes hypothyroidism in some patients with goitrous Hashimoto's disease.


2006 ◽  
Vol 191 (1) ◽  
pp. 221-228 ◽  
Author(s):  
Bénédicte Rabier ◽  
Allan J Williams ◽  
Frederic Mallein-Gerin ◽  
Graham R Williams ◽  
O Chassande

The active thyroid hormone, triiodothyronine (T3), binds to thyroid hormone receptors (TR) and plays an essential role in the control of chondrocyte proliferation and differentiation. Hypo- and hyperthyroidism alter the structure of growth plate cartilage and modify chondrocyte gene expression in vivo, whilst TR mutations or deletions in mice result in altered growth plate architecture. Nevertheless, the particular roles of individual TR isoforms in mediating T3 action in chondrocytes have not been studied and are difficult to determine in vivo because of complex cellular and molecular interactions that regulate growth plate maturation. Therefore, we studied the effects of TRα and TRβ on chondrocyte growth and differentiation in primary cultures of neonatal rib chondrocytes isolated from TRα- and TRβ-deficient mice. T3 decreased proliferation but accelerated differentiation of rib chondrocytes from wild-type mice. T3 treatment resulted in similar effects in TRα-deficient chondrocytes, but in TRβ-deficient chondrocytes, all T3 responses were abrogated. Furthermore, T3 increased TRβ1 expression in wild-type and TRα-deficient chondrocytes. These data indicate that T3-stimulated differentiation of primary rib chondrocytes in vitro requires TRβ and suggest that the TRβ1 isoform mediates important T3 actions in mouse rib chondrocytes.


2015 ◽  
Vol 173 (3) ◽  
pp. 333-340 ◽  
Author(s):  
Mitsuru Ito ◽  
Akira Miyauchi ◽  
Shino Kang ◽  
Mako Hisakado ◽  
Waka Yoshioka ◽  
...  

ObjectiveWe and others recently reported that in total thyroidectomy (TT), serum triiodothyronine (T3) levels during levothyroxine (l-T4) therapy were low compared to the preoperative levels, suggesting that the presence of the thyroid tissue affects the balances of serum thyroid hormone levels. However, the effects of remnant thyroid tissue on these balances in thyroidectomized patients have not been established.MethodsWe retrospectively studied 253 euthyroid patients with papillary thyroid carcinoma who underwent a TT or hemithyroidectomy (HT). We divided the cases into the TT+supplementall-T4(+l-T4) group (n=103); the HT+l-T4group (n=56); and the HT-alone group (n=94). We compared the postoperative serum levels of free T4(FT4) and free T3(FT3) and the FT3/FT4ratio in individual patients with those of controls matched by serum TSH levels.ResultsThe TT+l-T4group had significantly higher FT4(P<0.001), lower FT3(P<0.01) and lower FT3/FT4(P<0.001) levels compared to the controls. The HT+l-T4group had FT4, FT3and FT3/FT4levels equivalent to those of the controls. The HT-alone group had significantly lower FT4(P<0.01), equivalent FT3(P=0.083), and significantly higher FT3/FT4(P<0.001) ratios than the controls.ConclusionsThe presence of the remnant thyroid tissue was associated with different thyroid hormone balances in thyroidectomized patients, suggesting that T3production by remnant thyroid tissue has a substantial effect on the maintenance of postoperative serum T3levels.


Blood ◽  
2009 ◽  
Vol 114 (22) ◽  
pp. 675-675
Author(s):  
Eva Martinez-Garcia ◽  
Relja Popovic ◽  
Dong-Joon Min ◽  
Christine Will ◽  
Julia Meyer ◽  
...  

Abstract Abstract 675 The multiple myeloma SET domain (MMSET) gene is fused to the immunoglobulin locus in t(4;14)-associated multiple myeloma, and MMSET levels are elevated in these patients relative to other myeloma cases and normal cells. MMSET contains several domains commonly found in chromatin regulators including the PHD domain, PWWP domain and SET domain; responsible for histone methyl transferase (HMT) activity. What histone residues are methylated by MMSET in vivo has been uncertain. A well-folded, highly active form of the MMSET SET domain made in bacteria was promiscuous, methylating the H3K36, H3K27 and H4K20 residues of native histone as well as itself. To determine how MMSET affects chromatin in vivo and to identify genes regulated by MMSET, we engineered t(4;14)+ KMS11 cells with a tetracycline-inducible shRNA, leading to a >90% decrease in MMSET expression. Upon loss of MMSET expression, there was a striking decrease of trimethylated histone 3, lysine 36 (H3K36me3), a mark of transcriptional elongation and repression of intragenic transcription. At the same time, loss of MMSET expression was associated with a strong increase in H3K27me3, a chromatin mark associated with gene repression. For gain-of-function studies, the overexpressed MMSET allele in KMS11 cells was disrupted by homologous recombination (KMS11-TKO). KMS11-TKO cells, stably infected with a retrovirus carrying MMSET, displayed high levels of H3K36me3 and loss of H3K27me3. A specific mutation (Y1118A) in the SET domain of MMSET, predicted from crystal structure models to be required for histone binding, abrogated HMT activity of MMSET in vitro. Accordingly expression of MMSET Y1118A in KMS11-TKO cells failed to increase H3K36me3 levels. Another mutant, F1177A actually increased H3K36me3 levels above those stimulated by wild-type MMSET itself, most likely due to an expanded “pocket” within the SET domain that removed steric obstacles to the conversion of H3K36 from the mono-methyl to tri-methyl state. Collectively, these data indicate that H3K36 is a major methylation target of MMSET in vivo. To determine the genes regulated by MMSET and the importance of histone methylation in MMSET action, we profiled gene expression in both gain and loss-of-function systems using Illumina HumanWG-6 v3.0 expression arrays. We compared these gene lists with the top 2000 genes bound by MMSET as determined in a ChIP-on-chip assay using NimbleGen 2.7kb promoter arrays. MMSET knockdown affected expression of 1845 genes (FC>1.5, p<0.05); 931 were upregulated and 914 had reduced expression levels. Among these, 192 genes were also bound by MMSET. Re-expression of MMSET in KMS11-TKO cells led to increased expression of 749 genes while 788 genes were downregulated; 176 of these genes were also bound by MMSET. There were 38 genes that were bound by MMSET and regulated in both systems, including BMF, BTG2 and TP53INP1. These genes implicated in apoptosis represent potential direct transcriptional targets of MMSET. Furthermore, functional annotation of genes bound and regulated by MMSET in either the knockdown or repletion system, using Ingenuity Pathway Analysis, showed enrichment of genes implicated in the regulation of cell death and the p53 pathway (e.g. BAX, BCL2, CASP6), the cell cycle (CCNE2, E2F2, TP53INP1, CDC25A) and integrin-mediated signaling (ACTB, CDC42, ITGAL). The effect of MMSET on integrin signaling is of interest given that loss of MMSET expression or repletion of KMS11-TKO cells with MMSET altered the adhesive and growth properties of KMS11 cells. Finally, gene expression changes were contrasted between re-expression of wild-type MMSET and catalytically inactive MMSET Y1118A. Strikingly, the Y1118A mutant, which was deficient in altering cell adhesion and which did not change bulk histone methylation, altered expression of 1209 genes, 50% overlapping with those regulated by wild-type MMSET. Genes regulated by MMSET and the SET domain mutant were enriched mostly in cellular metabolism pathways (FDPS, IDI1, MVK) suggesting that effects on the cell cycle, adhesion and p53 pathways required the HMT activity of MMSET. These data indicate that MMSET can regulate genes in a HMT dependent and independent manner. Furthermore, MMSET target genes may be both activated and repressed upon changes in MMSET levels, indicating a complex interplay with the transcriptional machinery, likely through interactions with other transcriptional co-factors. Disclosures: No relevant conflicts of interest to declare.


2020 ◽  
Vol 2020 ◽  
pp. 1-8
Author(s):  
Fumiyoshi Yakou ◽  
Hirotsugu Suwanai ◽  
Takuya Ishikawa ◽  
Mariko Itou ◽  
Jumpei Shikuma ◽  
...  

Congenital hypothyroidism (CH) is the most prevalent congenital endocrine disorder and causes mental retardation. A male Japanese patient with first cousin marriage parents was diagnosed as CH at 10 months. He was born before introduction of mass screening for CH. With continuous thyroid hormone replacement therapy, normal thyroid hormone status was maintained until adulthood. Genetic screening of next-generation sequencing was performed at the age of 52 years, and we identified a new homozygous thyroid peroxidase (TPO) gene mutation (GRCh38.p13, chromosome 2 at position 1493997, c.1964 G>T, p.Cys655Phe). TPO is an important enzyme to produce thyroid hormone. As demonstrated by a homology analysis of TPO proteins among different species, cysteine 655 residue is highly conserved, suggesting an important role in maintaining TPO function and structure. An in silico study with three-dimensional structure of the novel mutation was performed and suggested that the mutation abolished disulfide bond between cysteines at positions 598 and 655. An in vitro functional analysis using HEK293 cells revealed that TPO activity of the mutant was significantly impaired compared with that of the wild type. Furthermore, study of immunohistochemistry showed that localization of TPO in cells did not differ between the wild type and the mutant. In conclusion, this single disulfide bond loss mutation of a new TPO homozygous mutation, p.Cys655Phe, reduced TPO activity and caused congenital hypothyroidism without affecting subcellular localization of TPO proteins.


1997 ◽  
Vol 17 (12) ◽  
pp. 7195-7207 ◽  
Author(s):  
J S Qi ◽  
V Desai-Yajnik ◽  
Y Yuan ◽  
H H Samuels

Thyroid hormone receptor (T3R) is a member of the steroid hormone receptor gene family of nuclear hormone receptors. In most cells T3R activates gene expression only in the presence of its ligand, L-triiodothyronine (T3). However, in certain cell types (e.g., GH4C1 cells) expression of T3R leads to hormone-independent constitutive activation. This activation by unliganded T3R occurs with a variety of gene promoters and appears to be independent of the binding of T3R to specific thyroid hormone response elements (TREs). Previous studies indicate that this constitutive activation results from the titration of an inhibitor of transcription. Since the tumor suppresser p53 is capable of repressing a wide variety of gene promoters, we considered the possibility that the inhibitor is p53. Evidence to support this comes from studies indicating that expression of p53 blocks T3R-mediated constitutive activation in GH4C1 cells. In contrast with hormone-independent activation by T3R, p53 had little or no effect on T3-dependent stimulation which requires TREs. In addition, p53 mutants which oligomerize with wild-type p53 and interfere with its function also increase promoter activity. This enhancement is of similar magnitude to but is not additive with the stimulation mediated by unliganded T3R, suggesting that they target the same factor. Since p53 mutants are known to target wild-type p53 in the cell, this suggests that T3R also interacts with p53 in vivo and that endogenous levels of p53 act to suppress promoter activity. Evidence supporting both functional and physical interactions of T3R and p53 in the cell is presented. The DNA binding domain (DBD) of T3R is important in mediating constitutive activation, and the receptor DBD appears to functionally interact with the N terminus of p53 in the cell. In vitro binding studies indicate that the T3R DBD is important for interaction of T3R with p53 and that this interaction is reduced by T3. These findings are consistent with the in vivo studies indicating that p53 blocks constitutive activation but not ligand-dependent stimulation. These studies provide insight into mechanisms by which unliganded nuclear hormone receptors can modulate gene expression and may provide an explanation for the mechanism of action of the v-erbA oncoprotein, a retroviral homolog of chicken T3R alpha.


Endocrinology ◽  
2005 ◽  
Vol 146 (6) ◽  
pp. 2620-2628 ◽  
Author(s):  
Masayuki Yamaguchi ◽  
Naoshi Ogata ◽  
Yusuke Shinoda ◽  
Toru Akune ◽  
Satoru Kamekura ◽  
...  

Abstract Bone anabolic action of PTH has been suggested to be mediated by induction of IGF-I in osteoblasts; however, little is known about the molecular mechanism by which IGF-I leads to bone formation under the PTH stimulation. This study initially confirmed in mouse osteoblast cultures that PTH treatment increased IGF-I mRNA and protein levels and alkaline phosphatase activity, which were accompanied by phosphorylations of IGF-I receptor, insulin receptor substrate (IRS)-1 and IRS-2, essential adaptor molecules for the IGF-I signaling. To learn the involvement of IRS-1 and IRS-2 in the bone anabolic action of PTH in vivo, IRS-1−/− and IRS-2−/− mice and their respective wild-type littermates were given daily injections of PTH (80 μg/kg) or vehicle for 4 wk. In the wild-type mice, the PTH injection increased bone mineral densities of the femur, tibia, and vertebrae by 10–20% without altering the serum IGF-I level. These stimulations were similarly seen in IRS-2−/− mice; however, they were markedly suppressed in IRS-1−/− mice. Although the PTH anabolic effects were stronger on trabecular bones than on cortical bones, the stimulations on both bones were blocked in IRS-1−/− mice but not in IRS-2−/− mice. Histomorphometric and biochemical analyses showed an increased bone turnover by PTH, which was also blunted by the IRS-1 deficiency, though not by the IRS-2 deficiency. These results indicate that the PTH bone anabolic action is mediated by the activation of IRS-1, but not IRS-2, as a downstream signaling of IGF-I that acts locally as an autocrine/paracrine factor.


Sign in / Sign up

Export Citation Format

Share Document